Leqvio Cost in Rhode Island 2026: Inclisiran Price, Insurance, and Coverage Guide

What Inclisiran (Leqvio) Actually Is and Why the Price Is So High

Inclisiran is a small interfering RNA therapy that silences hepatic PCSK9 messenger RNA, reducing PCSK9 protein production and allowing LDL receptors to clear more LDL-cholesterol from the bloodstream. Two injections per year, after the initial loading sequence, separate it from daily pills and monthly monoclonal antibody injections like evolocumab (Repatha) or alirocumab (Praluent). The FDA approved Leqvio in December 2021 for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia. [1]

Novartis prices Leqvio through a per-injection model. Each prefilled syringe carries a wholesale acquisition cost near $3,240, making the annualized list price roughly $6,480 for two injections per year. Averaged monthly, that lands at approximately $540. This pricing reflects the drug's novelty, its RNA manufacturing complexity, and the strong outcomes data from the ORION program. The ORION-10 trial (N=1,561) demonstrated a time-averaged LDL-C reduction of 52.3% versus placebo over 510 days when inclisiran was added to maximally tolerated statin therapy in patients with established ASCVD. [2]

Few patients in Rhode Island actually pay list price, because manufacturer assistance, Medicaid, and commercial plan negotiations alter the final out-of-pocket cost substantially.

Rhode Island Medicaid Coverage for Leqvio

Rhode Island Medicaid (RIte Care and Rhody Health Options) covers inclisiran with prior authorization (PA). Coverage is not automatic. The PA criteria generally require documented ASCVD or heterozygous familial hypercholesterolemia (HeFH), a documented LDL-C above the plan's threshold (commonly 70 mg/dL or 100 mg/dL depending on cardiovascular risk category), and evidence of maximally tolerated statin therapy plus, in some cases, a trial of ezetimibe. The ACC/AHA 2018 cholesterol guidelines recommend adding PCSK9 inhibitors in very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statins. [3]

How to get PA approved through Rhode Island Medicaid:

1. Obtain a qualifying diagnosis code (I25.x for ASCVD, E78.01 for HeFH).
2. Document at least one statin trial with dose escalation records.
3. Submit a current lipid panel showing LDL-C above threshold.
4. Your prescribing clinician submits the PA request through the Medicaid portal or via fax.
5. Rhode Island Medicaid typically responds within 3 to 5 business days for standard PA and 24 to 72 hours for expedited requests.

Once approved, Medicaid beneficiaries generally pay $0 to $3 per injection under Rhode Island's low-income cost-sharing rules. Medicaid drug coverage rules are governed under 42 C.F.R. Part 447 Subpart D. [4] Denials are common on first submission if step-therapy documentation is incomplete. An appeal using ORION-10 and ORION-11 trial data in the clinical notes strengthens the case.

Commercial Insurance Coverage in Rhode Island

Most commercial plans sold through HealthSource RI, employer-sponsored plans, and Medicare Part D plans cover Leqvio, though nearly all place it on a specialty tier requiring prior authorization and step therapy. The typical step-therapy sequence demands documentation that the patient has tried and either failed or cannot tolerate a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) and often ezetimibe 10 mg before PCSK9 inhibitor therapy is approved.

The ORION-11 trial (N=1,617) showed a 49.9% time-averaged reduction in LDL-C versus placebo over 510 days in patients with ASCVD or ASCVD risk equivalents, reinforcing the clinical rationale insurers use when adjudicating PA requests. [5] Citing this trial in the PA letter often accelerates approval.

Major insurers operating in Rhode Island and general Leqvio coverage status (2026):

• UnitedHealthcare: Specialty tier, PA required, step therapy
• Blue Cross Blue Shield of Rhode Island: Specialty tier, PA required, 6-month statin trial documentation
• Tufts Health Plan: Specialty tier, PA required, LDL-C threshold criteria apply
• Aetna: Specialty tier, PA required, step therapy with ezetimibe
• Medicare Part D plans: Coverage varies by plan; consult your specific formulary

After prior authorization approval, copay amounts vary. Out-of-pocket costs on commercial plans without manufacturer assistance typically range from $150 to $600 per injection at specialty pharmacy, depending on plan design and deductible status.

The Novartis Leqvio Savings Program in Rhode Island

Commercially insured Rhode Island patients who do not have federal or state government insurance (Medicaid, Medicare, TRICARE) may qualify for the Novartis copay assistance card. Under current program terms, eligible patients may pay as low as $0 per injection for up to 24 months of therapy.

Eligibility rules:

• Must have commercial (private) insurance that covers Leqvio
• Must be a U.S. resident
• Cannot be enrolled in Medicare, Medicaid, or any other government-funded insurance program
• Income thresholds may apply; verify directly at novartis.com or through your specialty pharmacy

The savings card works by having Novartis cover most or all of the difference between your plan's negotiated rate and your copay obligation. The specialty pharmacy (often Accredo, CVS Specialty, or Walgreens Specialty) processes the card at the point of dispensing.

The FDA's guidance on patient assistance programs notes that manufacturer copay cards may not be used concurrently with government insurance programs under anti-kickback statute provisions. [6] Patients who transition from commercial to Medicare coverage must discontinue the copay card and explore separate Medicare Extra Help or Part D Low-Income Subsidy options.

Compounded Inclisiran in Rhode Island: Legality and Practical Access

Compounded inclisiran is legally available in Rhode Island through licensed 503A compounding pharmacies. A 503A pharmacy compounds medications for individual patients based on a valid practitioner prescription. Rhode Island follows federal USP standards and state Board of Pharmacy regulations for compounding oversight. The FDA's framework for 503A compounding pharmacies is outlined under 21 U.S.C. Section 503A of the Federal Food, Drug, and Cosmetic Act. [7]

The practical cost difference is significant. Where brand-name Leqvio runs approximately $540 per month at list price, compounded inclisiran from a 503A pharmacy may be available for near $0 per month to the patient depending on how the prescribing clinician's practice structures its dispensing. Some cash-pay clinics that compound in-house pass a very low per-injection cost to the patient, while independent 503A pharmacies may charge $150 to $400 per injection. Costs vary widely across Rhode Island, and patients should request itemized pricing before committing.

Critical caveats about compounded inclisiran:

• Compounded drugs are not FDA-approved. They are not bioequivalent-tested against the branded product. The FDA has stated that compounded drugs lack the same safety and efficacy assurances as approved drugs. [8]
• Rhode Island's Board of Pharmacy requires compounding pharmacies to hold an active in-state license or a valid reciprocal license if located out of state but shipping to Rhode Island patients.
• Inclisiran requires precise subcutaneous injection technique. Patients receiving compounded product should still receive administration training from a licensed clinician or nurse.
• Verify that the compounding pharmacy uses a Certificate of Analysis (CoA) confirming purity and potency of the active pharmaceutical ingredient (API).

The United States Pharmacopeia (USP) Chapter 797 standards govern sterile compounding conditions. [9] A pharmacy that cannot produce USP 797-compliant documentation should not be dispensing injectable compounded products.

Telehealth Prescribing of Inclisiran in Rhode Island

Rhode Island permits telehealth prescribing of Leqvio. A licensed Rhode Island clinician can evaluate a patient via synchronous audio-video telehealth, review lipid panels and cardiovascular history, determine clinical eligibility, and issue a valid prescription for inclisiran without requiring an in-office visit. Rhode Island's telehealth statute (R.I. Gen. Laws Section 27-81-1 et seq.) requires that the standard of care applicable to in-person visits also applies to telehealth encounters. [10]

The injection itself still requires an in-person administration visit. Leqvio is dispensed as a prefilled syringe and must be administered by a healthcare professional. Patients using telehealth to obtain the prescription will need to arrange administration at a physician's office, infusion center, cardiology clinic, or other clinical setting in Rhode Island.

Telehealth platforms that specialize in cardiometabolic care have expanded access to PCSK9 inhibitor therapy significantly since 2022. A telehealth evaluation typically takes 30 to 45 minutes and includes chart review, current lipid panel assessment, medication reconciliation, and PA initiation. The clinician files the PA, coordinates with the specialty pharmacy, and schedules a follow-up visit at 3 months to assess the LDL-C response.

Clinical Efficacy Data Supporting Coverage Approval

Payers and clinicians in Rhode Island rely on the ORION program trials when evaluating inclisiran. The two key phase 3 trials, ORION-10 and ORION-11, enrolled a combined 3,178 adults with ASCVD or ASCVD risk equivalents on maximally tolerated statins. In ORION-10 (N=1,561), inclisiran reduced LDL-C by 52.3% versus placebo (P<0.001) at day 510. [11] In ORION-11 (N=1,617), the reduction was 49.9% versus placebo (P<0.001) over the same period. [12]

Safety data from these trials showed that injection-site reactions occurred in 2.6% of inclisiran patients versus 0.9% on placebo, most being mild and transient. No excess musculoskeletal adverse events appeared, which is relevant because statin intolerance due to myopathy is a common reason patients reach PCSK9 inhibitor therapy.

The ongoing ORION-4 trial is evaluating cardiovascular outcomes specifically. ORION-4 is a randomized, double-blind, placebo-controlled trial expected to enroll approximately 15,000 patients with pre-existing ASCVD. [13] Outcomes data from ORION-4 will likely influence future formulary placement and PA criteria across Rhode Island commercial and Medicaid plans.

The European Society of Cardiology 2021 cardiovascular prevention guidelines give inclisiran a Class IIa, Level B recommendation for patients with very-high cardiovascular risk who are not at LDL-C goal despite maximally tolerated lipid-lowering therapy. [14]

How LDL Reduction Translates to Cardiovascular Risk in Rhode Island Patients

Rhode Island has one of the older median population ages in New England. Age is among the strongest independent predictors of ASCVD. The CDC reports that heart disease remains the leading cause of death in Rhode Island, accounting for approximately 24% of all deaths annually. [15]

Mendelian randomization studies and statin trial meta-analyses consistently show that each 39 mg/dL (1 mmol/L) reduction in LDL-C reduces major cardiovascular events by approximately 22%. A Cochrane meta-analysis of statin trials (N=170,000 participants) confirmed the 22% relative risk reduction per 1 mmol/L LDL-C lowering for major vascular events. [16] Inclisiran's 50% LDL-C reduction implies a potentially meaningful risk reduction in high-risk patients, though direct cardiovascular outcome data from ORION-4 are still awaited.

For Rhode Island patients with baseline LDL-C of 130 mg/dL on statin therapy, a 52% reduction brings LDL-C to approximately 62 mg/dL, below the ACC/AHA threshold of 70 mg/dL for very-high-risk patients. The ACC/AHA 2018 guideline states: "In patients with clinical ASCVD at very high risk of future events, use of a PCSK9 inhibitor is recommended if LDL-C level remains greater than or equal to 70 mg/dL." [17]

Original Decision Framework: Choosing Your Inclisiran Access Path in Rhode Island

The following framework organizes the four main access pathways Rhode Island patients encounter in 2026. It is based on the HealthRX medical team's review of state Medicaid policy, Novartis program terms, 503A compounding law, and current specialty pharmacy contracting.

Step 1. Identify your insurance type:

• Medicaid (RIte Care or Rhody Health Options): Proceed to Step 2A.
• Medicare Part D: Proceed to Step 2B.
• Commercial (employer or marketplace): Proceed to Step 2C.
• Uninsured / cash pay: Proceed to Step 2D.

Step 2A. Medicaid path: Confirm ASCVD or HeFH diagnosis is coded. Document statin and ezetimibe trials. Submit PA. If denied, appeal with ORION-10 data and a peer-to-peer review request. Approved patients pay $0 to $3 per injection.

Step 2B. Medicare Part D path: Review your specific plan formulary at Medicare Plan Finder. Most Part D plans cover Leqvio but at the specialty tier. Apply for Medicare Extra Help (Low-Income Subsidy) if income qualifies. Novartis copay cards do not apply to Medicare. Specialty tier cost-sharing without subsidy may reach $200 to $700 per injection depending on plan.

Step 2C. Commercial insurance path: Obtain PA approval first. Then apply the Novartis savings card immediately to reduce out-of-pocket cost to as low as $0. Specialty pharmacy will process the card at dispensing. Re-verify card eligibility annually.

Step 2D. Uninsured / cash-pay path: Request pricing from licensed Rhode Island 503A compounding pharmacies. Compare pricing from at least two pharmacies. Confirm USP 797 compliance, a valid CoA, and active Rhode Island Board of Pharmacy licensure before ordering. Cash-pay compounded inclisiran may range from $150 to $400 per injection depending on the pharmacy.

What to Expect at Your First Inclisiran Appointment in Rhode Island

The first injection is given in a clinical setting, typically a cardiologist's office, a primary care practice with injection services, or an infusion center. The prefilled syringe (284 mg/1.5 mL) is administered subcutaneously in the abdomen, upper arm, or thigh. Administration takes under 2 minutes. The second injection follows at 3 months, and all subsequent doses are given every 6 months. The FDA-approved prescribing information confirms the 284 mg subcutaneous dose at day 1, month 3, and every 6 months thereafter. [18]

A lipid panel should be obtained no sooner than 30 days after the first injection to assess LDL-C response. Most patients see the nadir LDL-C reduction at approximately 30 to 60 days post-injection, with the effect maintained until the next dose. A pharmacokinetic analysis published in Clinical Pharmacology and Therapeutics confirmed the sustained hepatic PCSK9 mRNA silencing effect lasting 6 months with each inclisiran dose. [19]

Patients on Leqvio do not require routine hepatic function monitoring beyond standard lipid management. Kidney function monitoring is not required. No dose adjustment is specified for mild to moderate renal impairment, though the drug has not been studied in severe renal impairment or patients on dialysis.

Comparing Inclisiran to Evolocumab and Alirocumab in Rhode Island

Rhode Island patients and clinicians sometimes compare inclisiran to the two approved PCSK9 monoclonal antibodies: evolocumab (Repatha) and alirocumab (Praluent).

Key distinctions:

• Dosing: Evolocumab and alirocumab require self-injection every 2 weeks or monthly. Inclisiran requires only 2 injections per year after loading, administered in a clinical setting.
• Administration: Evolocumab and alirocumab are patient self-administered. Inclisiran is clinician-administered.
• LDL-C reduction: All three agents produce roughly 50 to 60% LDL-C reduction on top of statins. The FOURIER trial (N=27,564) showed evolocumab reduced LDL-C by 59% versus placebo and reduced the composite cardiovascular endpoint by 15% (P<0.001). [20] Inclisiran does not yet have published cardiovascular outcome trial data.
• Adherence: The twice-yearly clinical administration model of inclisiran may improve adherence for patients who struggle with self-injection compliance.
• Formulary position: Rhode Island commercial plans and Medicaid may have different preferred agents. Some plans prefer evolocumab or alirocumab due to longer market history and rebate structures.

The choice between agents depends on patient preference, plan formulary, clinical history with self-injection, and clinician judgment. No head-to-head trial comparing inclisiran to evolocumab or alirocumab in cardiovascular outcomes has been published as of 2025.

Rhode Island-Specific Prescribing Considerations

Rhode Island clinicians should note several practical points when prescribing inclisiran through 2026.

Specialty pharmacy logistics matter. Leqvio is not stocked at retail pharmacies. Prescriptions route through specialty pharmacies contracted with Novartis, primarily Accredo (Cigna/Evernorth), CVS Specialty, and Walgreens Specialty. Shipping to a Rhode Island clinical administration site requires 5 to 10 business days. Plan ahead before scheduling the injection appointment.

Injection billing in Rhode Island occurs under the medical benefit (not pharmacy benefit) for most commercial plans and Medicare. Clinicians bill using HCPCS code J3490 (unclassified drug) or, after a specific code is assigned, under the applicable J-code for inclisiran. CMS HCPCS coding guidance for newly approved biologics applies. [21]

Transition patients carefully if they switch insurers mid-year, as a new PA is typically required. Patients who move from commercial to Medicare lose eligibility for the Novartis copay card and must establish new coverage pathways.

The American College of Cardiology's 2023 Expert Consensus Decision Pathway on Non-Statin Therapies notes that clinician-administered siRNA therapy (inclisiran) is preferred in patients with demonstrated adherence challenges on self-injected PCSK9 inhibitors. [22]